In the subgroup analysis of three clinical studies [43–45], the CR rates of venetoclax-based drug regimen in R/R AML patients with IDH mutations were 1/11, 2/12 and 3/5, respectively, but the sample size of these studies was very small. This evidence concerns the gene IDH2 and acute myeloid leukemia.